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Abstract
Rationale Preclinical reconsolidation research offers the first
realistic opportunity to pharmacologically weaken the mal-
adaptive memory structures that support relapse in drug ad-
dicts. N-methyl D-aspartate receptor (NMDAR) antagonism
is a highly effective means of blocking drug memory
reconsolidation. However, no research using this approach
exists in human addicts.
Objectives The objective of this study was to assess the po-
tential and clinical outcomes of blocking the reconsolidation
of cue-smoking memories with memantine in quitting
smokers.
Methods Fifty-nine dependent and motivated to quit smokers
were randomised to one of three groups receiving the follow-
ing: (1) memantine with or (2) without reactivation of asso-
ciative cue-smoking memories or (3) reactivation with place-
bo on their target quit day in a double-blind manner.
Participants aimed to abstain from smoking for as long as
possible. Levels of smoking and FTND score were assessed
prior to intervention and up to a year later. Primary outcome
was latency to relapse. Subjective craving measures and atten-
tional bias to smoking cues were assessed in-lab.
Results All study groups successfully reduced their smoking
up to 3 months. Memantine in combination with smoking
memory reactivation did not affect any measure of smoking
outcome, reactivity or attention capture to smoking cues.
Conclusions Brief exposure to smoking cues with memantine
did not appear to weaken these memory traces. These findings
could be due to insufficient reconsolidation blockade by
memantine or failure of exposure to smoking stimuli to
destabilise smoking memories. Research assessing the treat-
ment potential of reconsolidation blockade in human addicts
should focus on identification of tolerable drugs that reliably
block reward memory reconsolidation and retrieval proce-
dures that reliably destabilise strongly trained memories.
Keywords Memantine . Smoking cessation . Smokers .
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Introduction
Substance use disorders (SUDs) involve lasting pathological
adaptations in reward learning (Hyman et al. 2006) and moti-
vational (Robinson and Berridge 1993, 2001) memory circuits
encoding relationships between environmental stimuli or
‘cues’ and drug availability and reward value, such that these
cues motivate drug seeking, craving and relapse when en-
countered (Kalivas and Volkow 2005). These ‘maladaptive
motivational memories’ (MMMs) underlie the long-term hy-
persensitivity to drug-related stimuli and quiescent suscepti-
bility to relapse in ex-users that typifies addiction (Milton and
Everitt 2012).
Extant pharmacotherapies and psychotherapies do not di-
rectly modulate MMMs. Some interventions have attempted
to inhibit MMMs by augmenting the strength of extinction
learning (Kamboj et al. 2012; Kamboj et al. 2011), but these
have met with limited success. This is likely because extinc-
tion does not directly weaken MMMs and is therefore only as
effective as the continued capacity of extinction memories to
inhibit prepotent MMMs. Brief extinction learning is largely
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insufficient to compete with long-established maladaptive
memories, and the effects of putative consolidation enhancers
(Das and Kamboj 2012) are too modest to redress this imbal-
ance in memory strength.
An alternative approach that aims to directly weaken
MMMs during memory reconsolidation has inspired much
interest in the past decade. ‘Reconsolidation’ is a term used
to refer to the process of destabilisation and subsequent
restabilisation of memory traces upon recall (Nader et al.
2000) allowing prescient new information to be incorporated
into existing memory traces to keep them up-to-date (Lee
2009). The restabilisation of appetitive memories is dependent
upon cascades of de novo protein synthesis via activation of
the N-methyl-D-aspartate receptor (NMDAR) and the tran-
scription factor, Zif268 (Lee and Hynds 2013). As such,
antagonising NMDARs (Lee and Everitt 2008; Milton et al.
2008a), interfering with gene transcription or inhibiting pro-
tein synthesis (Blundell et al. 2008; Nader et al. 2000) follow-
ingmemory destabilisation can greatly weakenmemory traces
in laboratory animals. Reconsolidation research therefore of-
fers the first credible opportunity for directly weakening
MMMs and potentially reducing long-term relapse rates in
addicts (Milton and Everitt 2012).
Despite the promise of this approach, there are major
obstacles hindering its application in human addicts.
Primary amongst these are the sensitivity of memory
destabilisation to parameters of retrieval (Lee 2009;
Pedreira et al. 2004), age and strength of the retrieved
memory and the lack of compounds available for human
use known to block restabilisation. Length of the memory
retrieval session, number of cue presentations and similar-
ity of retrieval to learning all constrain destabilisation of
memories, determining the switch between the mutually
exclusive (Merlo et al. 2014) processes of reconsolidation
and extinction (Osan et al. 2011; Pérez-Cuesta and
Maldonado 2009; Suzuki et al. 2004). The effect of these
parameters may all be mediated by their impact on the
generation of mismatch, or prediction error, during re-
trieval (Sevenster et al. 2013), which is necessary for
memory destabilisation.
Older, more robust memories are generally less susceptible
to destabilisation when retrieved (Robinson and Franklin
2010). Although paradigms involving instrumental
responding may involve hundreds of action-outcome pairings
and still show reconsolidation blockade (Lee et al. 2006;
Milton et al. 2008a; Milton et al. 2008b), in human addictions
such as smoking and alcoholism,MMMs are formed over tens
or hundreds of thousands of action-reinforcement pairings
(e.g. a 20-per-day smoker, taking 15 drags per cigarette, for
2 years=146,000 reinforced inhalation actions) and should
therefore be considered extremely robust. Despite highly
promising findings using cue exposure following
destabilisation of cue-drug memories in heroin users (Xue
et al. 2012), the destabilisation of cue-smoking or cue-
drinking MMMs has not yet been shown in humans and,
given their training history, may not even be possible.
We recently demonstrated that of two classes of drugs that
show trans la t iona l promise for b locking MMM
reconsolidation, NMDAR antagonists and β-blockers,
NMDAR antagonists display much more robust effects than
β-adrenergic antagonists (Das et al. 2013). Only one study
(Saladin et al. 2013) has attempted to translate these preclini-
cal findings into humans. This attempt to use propranolol to
disrupt reconsolidation in cocaine-dependent individuals
found the relatively modest effects predicted from the meta-
analytic findings. Although short-term effects of propranolol
were found, lasting effects (which would be expected if
reconsolidation were interrupted) were not.
To date, no research exists examining the potential of in-
terfering withMMM reconsolidation byNMDAR antagonism
in human addicts. While NMDAR antagonists interfere ro-
bustly with memory restabilisation in animals, they are also
often dissociative, psychotomimetic (Muetzelfeldt et al. 2008)
and neurotoxic (Fix et al. 1993), limiting their utility in human
addicts. Of the very limited class of NMDAR antagonists
available for human use that do not produce these effects,
memantine is a potentially promising reconsolidation-
disrupting agent in humans, with translational potential sup-
ported by the observation that it interferes with MMM
restabilisation in rodents (Alaghband and Marshall 2013;
Popik et al. 2006).
Memantine is very well tolerated and does not exhibit the
side effects of other NMDAR antagonists at low doses
(Parsons et al. 1999). However, findings with memantine in
reconsolidation are inconsistent and species-dependent
(Samartgis et al. 2012). Further, due to the lack of human
MMM reconsolidation research and the novel pharmacody-
namics of memantine at the NMDA receptor (Rammes et al.
2008; Xia et al. 2010), there is very little information upon
which to base an experimental memantine dose. Meta-
analysis suggests a non-linear dose-response effect of MK-
801 on reward memory reconsolidation blockade, with low
doses exhibiting greater efficacy than moderate doses (Das
et al. 2013). Although memantine has lower NMDAR affinity
than MK-801 (Rammes et al. 2008), low doses of the drug
have been found to induce memory impairments in rats, with
higher doses generating an intolerable side effect profile
(Creeley et al. 2006). In cloned human receptors, memantine
in high concentrations antagonises both NMDARs and nico-
tinic acetylcholine receptors (Maskell et al. 2003). This lack of
specificity impedes the attribution of any observed effects to
glutamatergic reconsolidation systems.
Human research in smokers has utilised up to 40 mg
memantine. At this dose, memantine produces significant diz-
ziness, light-headedness, detachments from reality and tempo-
ral distortion and prevents the ‘buzz’ smokers experienced
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following a cigarette (Jackson et al. 2008). Appropriate dosing
should aim to minimise this side effect profile, maximise the
NMDAR specificity of memantine and avoid the potential dip
in efficacy of moderate-dose NMDA antagonism.
Given the great translational potential of NMDAergic hu-
man MMM reconsolidation blockade, but paucity of research
therein, we sought to establish proof-of-principle that
memantine could interfere with the reconsolidation of
MMMs in quitting tobacco smokers, a prototypical addicted
population, to reduce relapse and cognitive measures of
MMM strength.
Instead of conducting a premature and costly clinical trial,
we employed an experimental medicine approach that
capitalised on participants’ voluntary quitting. Following
memantine combined with smoking memory reactivation,
we sought evidence of NMDAR-mediated blockade of
MMM reconsolidation, as indicated by longer relapse latency,
fewer cigarettes smoked at follow-up and reduced dependence
score (primary outcomes) and reductions in cue reactivity and
an attentional bias measure of smoking cue motivational sa-
lience (secondary outcomes). Taking account of the aforemen-
tioned issues with dosing, a relatively low (compared to pre-
vious studies) dose of 10 mg memantine was selected.
Materials and methods
Participants and design
Based on a conservative effect size of r=0.35, power calcula-
tion for 0.8 power at α=0.05 yielded a required N of 57.
Assuming minimal attrition, 59 smokers were recruited via
internet advertisement. Inclusion criteria were ages >18<65,
scoring >4 on the Fagerstrom Test of Nicotine Dependence
(FTND) (Heatherton et al. 1991), smoking >10 cigarettes ev-
ery day, a strong desire to stop smoking and intending to
within 3 months and willingness to make a serious attempt
at sustained abstinence that could be timed with the first study
day. Exclusion criteria were current/history of mental health or
neurological conditions, concurrent addiction to any other
substance, use of any illicit drug more than once per week,
use of ketamine more than once per month, pregnancy or
breastfeeding and compromised renal or hepatic function. Of
the participants randomised to a group, four did not attend the
second study session and were lost to all further follow-up.We
utilised an intention-to-treat approach such that all participants
randomised contributed data to the statistical analyses. All
procedures were approved by the UCL ethics committee.
A randomised, double-blind, placebo-controlled design
assessed the effects of memantine on MMM reconsolidation.
Participants were randomly assigned to the following groups:
brief reactivation of smoking MMMs with memantine
(MEM+ REACT, N=19), reactivation of smoking MMMs
with placebo (PLA +REACT, N=20) or memantine without
reactivation of smoking MMMs (MEM no REACT, N=20).
Drug was 10 mg oral memantine hydrochloride (Namenda)
formulated in opaque gelatine capsules with lactose filler.
Placebos were matched lactose-only capsules.
Tasks and apparatus
Visual probe
Avisual probe task motivational salience of smoking cues on
day 8 of the study. As motivational salience is thought to be a
product of reward learning, weakening MMMs should result
in reduced salience of smoking cues and reduced attentional
bias to these cues. The task used two types of image pairs:
smoking pictures paired with composition-matched neutral
images (n=20) or control neutral-neutral (n=20) pairs. The
task and the images are described completely in the paper
from which they were taken (Mogg et al. 2003). Image pairs
appeared for 500 or 2000 ms and were replaced by probes
either contralateral or ipsilateral to the target (smoking-relat-
ed). Trial presentation was counterbalanced for duration, tar-
get side and probe/target congruence.
Smoking, subjective and physiological assessments
Primary outcomes of nicotine dependence and continuous lev-
el of smoking were assessed with the Fagerstrom Test of
Nicotine Dependence (FTND) (Heatherton et al. 1991) and a
daily online ‘smoking diary’ starting 1 week prior to day 1
(baseline) and continuously from then up to 3 weeks follow-
ing day 8. The smoking diary for each participant was checked
daily, and they were contacted by telephone to remind them to
fill it out if entries fell more than 24 h behind. The subjective
assessment battery consisted of the 10-item Questionnaire on
Smoking Urges (QSU) assessing craving (Tiffany and Drobes
1991); Mood and Physical Symptoms Scale (MPSS) (West
and Hajek 2004), assessing withdrawal-related symptoms;
Spielberger State-Trait Anxiety Index (STAI) (Spielberger
et al. 1970), assessing state and general anxiety levels;
Barratt Impulsiveness Scale (BIS), assessing levels of trait
impulsivity (Patton and Stanford 1995); Beck Depression
Inventory (BDI), measuring depressive symptomatology
(Beck et al. 1988); Temporal Experience of Pleasure Scale
(TEPS) assessing hedonic processing (Gard et al. 2006); and
Perceived Social Support scale, friend (PSS-FR) and family
(PSS-FA) (Procidano and Heller 1983) versions, assessing
supportive structures surrounding participants. This battery
of tests was included based upon previous research showing
that these constructs are important predictors of smoking ces-
sation success (Mermelstein et al. 1986; Powell et al. 2010;
Powell et al. 2004) in order to better assess changes that were
specifically manipulation-related.
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Single-item 100-mm VAS scales were used immediately
pre- and post-video to assess cue-induced craving during re-
activation. These scales required participants to mark down
the strength of their urge to smoke and were anchored ‘No
urge at all’ and ‘Strongest Urge Ever’. They were used in
place of the QSU as cue reactivity measures to provide rapid
momentary assessment, minimise completion time and inter-
ference with electrophysiological measures. Such scales have
high convergent validity with the QSU (West and Ussher
2010). Eye movement data during the visual probe were ac-
quired with a desktop-mounted Eyelink 1000 eye tracker (SR
Research, Ontario, Canada) with participants’ heads stabilised
70 cm from the 1024×768 monitor used to display all com-
puter tasks. Blood pressure was measured with an Omron
708-BT electronic blood pressure cuff (Omron, Japan) and
skin conductance and heart rate variability (HRV) were re-
corded using an Equivital EQo2 Lifemonitor belt and sensor
with auxiliary skin conductance electrodes (Hidalgo,
Cambridge, UK) attached to the medial phalanges of the par-
ticipants’ left hand with AMBU white sensors.
Procedure
The first study session (day 1) was arranged to fall on partic-
ipants’ target ‘quit day’. Participants filled out the daily online
smoking diary for the week preceding day 1. Participants were
asked to refrain from smoking for 1 h prior to the beginning of
day 1, to fast for at least 3 h and to avoid the use of alcohol or
any drug in the 24-h preceding sessions.
Day 1 (baseline/intervention)
Participants took the capsule memantine or placebo cap-
sule immediately after informed consent. Breath carbon
monoxide (CO) was then measured with a Micro+ CO
meter (Bedfont, UK). Participants then completed the
subjective assessment battery and a saccade/antisaccade
task and effort-based reward task, which are not reported
here. Participants then waited until 3.5 h had elapsed
since they took the capsule, based on oral memantine
reaching peak plasma concentrations at 3–7 h post-ad-
ministration, to coincide peak concentrations with the
reconsolidation window (at ~4 h post-pill). After the
break, participants were fitted with ECG and skin con-
ductance electrodes and began the retrieval procedure.
MMM/control retrieval
Smoking MMM reactivation stimuli were boxes containing
physical smoking cues (Marlboro cigarettes, lighter and ash-
tray) and six 30-s validated video clips depicting people
smoking in various locations with smoking paraphernalia.
Non-reactivation stimuli consisted of six similar 30-s clips that
did not depict smoking or smoking-related cues (Tong et al.
2007) and a box containing numbered cards and a pencil. The
boxes and videos were labelled so that the experimenter was
blind to their contents.
Participants were given the relevant in vivo stimuli box and
informed that they would receive on screen instructions before
watching some video clips. Prior to starting the videos, a 5-
min heart rate baseline, blood pressure and single-item craving
was recorded.
Before the videos, the on-screen instructions read as fol-
lows: BIn front of you is a box, please open the box now and
take note of its contents and leave it open until you are told to
close it. In the box there is [a lighter, cigarettes and ashtray/ a
deck of numbered cards, paper and a pencil]. These are for a
task that you may be required to perform after watching a
series of short videos. This task will be performed outside of
the building, with a different experimenter. When you are
watching the videos, try to imagine being in the depicted
scenes as much as possible, imagining the sights, smells, sen-
sations and sounds as if they were really there. You will be told
whether or not you need to complete the task after the videos
finish.^ The videos then played and after their conclusion
participants were informed that they would not complete the
task, to close the box and alert the experimenter. Another
blood pressure and single itemVAS craving measure was then
recorded, and a 5-min period of heart rate post-video collect-
ed. To ensure engagement with the reactivation procedure,
participants were then given space to write a summary of the
procedure that had happened, what they had seen in the
videos, what the videos and box reminded them of and what
they believed the task involved. Finally, participants guessed
whether they received drug or placebo. A schematic of the
testing order and timing on day 1 is shown in Fig. 1.
Day 8 (test)
Participants returned to the study centre and a carbon monox-
ide reading was taken. They then completed the subjective
assessment battery and in vivo/video ‘reactivation’ procedure
along with heart rate, blood pressure and craving measures to
assess changes in cue reactivity. Finally, the visual probe task
was completed and this concluded testing. Participants contin-
ued to fill out the smoking diary for three more weeks.
Participants were reimbursed at a rate of £8 per hour. To
incentivise compliance with smoking diary completion fol-
lowing day 8, payment was split between day 8 and 3 weeks
post-day 8, with half at each time point.
Follow-up measures were completed by telephone at ~3-
month intervals for up to 1 year. All participants were follow-
ed for at least 3 months and if their smoking returned to pre-
study levels, they were followed up no further. If participants
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became uncontactable, their scores on smoking-related prima-
ry outcomes were returned to baseline level.
Statistical approach
All data analysis was performed using IBM SPSS version 21
for Windows. Group assignment was only unblinded after
analysis was completed. Data were checked for normality,
homogeneity of variance and sphericity by inspection of his-
tograms and z-scored skewness/kurtosis, Levene’s test and
Mauchly’s test, respectively. Any outliers more than 3 stan-
dard deviations away from the sample mean for that variable
were replaced with a score falling 3 standard deviations from
the mean. Data were square root or log transformed where
skewed. If this did not normalise the distribution, non-
parametric equivalents of tests were used as appropriate.
Descriptive statistics represent untransformed data, unless
stated otherwise, in order to aid interpretation of results.
Where homogeneity of variance was violated in one-way
ANOVA, Welch’s F test is reported. Where sphericity was
violated, the Huynh-Feldt correction was applied to the de-
grees of freedom and significance levels. Uncorrected degrees
of freedom are reported here, with corrected p values. For
single time-point measurements, one-way ANOVAwas used
to assess group differences and for repeated measurements,
mixed ANOVA with a between-subjects factor of group was
used. Significant main effects and interactions in omnibus
ANOVAs were investigated with independent or paired sam-
ple t tests on marginal means, where appropriate. Survival
analysis on relapse latency was performed using Cox regres-
sion stratified by group. pairwise comparisons on k >2 effects
in omnibus ANOVAs were Bonferroni-corrected.
Results
To maintain clinical relevance, we employed an intention-to-
treat analysis with dropout coded as treatment failure and
scores on primary outcomes returned to baseline. For drop-
outs, visual probe data were imputed using the estimation
maximisation method as Little’s test indicated that data were
missing completely at random (χ2(69)=77.094, p=0.236).
Descriptive statistics for baseline measures are given in
Table 1. The groups differed only on craving, with higher
craving in MEM no REACT compared to PLAC +
REACT and marginally on BIS, with lower scores in
PLAC + REACT. All analyses were run with and without
these scores as covariates, and no substantive difference
was found, so reported statistics represent those without
covariates included. Compliance with filling out the
smoking diary was very good in all groups, with over
90 % days completed by all participants and no more than
1 day consecutively omitted by any participant that com-
pleted treatment. Mean per day smoking was therefore
calculated for the baseline and post-quit periods.
Changes in smoking behaviour
Initial analysis of follow-up data showed that no change in
smoking status occurred in any participants after the first 3-
month follow-up and that the majority of participants had
returned relapsed by this time. As such, the first 3-month
follow-up only is included in the subsequent statistical analy-
ses. Mixed 2 (day 1, day 8) × 3 (group) ANOVA found a
reduction in breath CO between days in all groups [time main
effect F(1,56)=141.822, p<0.001, ηp
2=0.717] but no group
Fig. 1 Schematic of testing order on study day 1. Day 8 followed an identical testing order, without drug administration or waiting period. The visual
probe was performed as the last task on this day
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or group×day interactions. A 3 (baseline week, post-quit
week, 3 months post-quit)×3 (group) ANOVA showed a re-
duction inmean daily number of cigarettes smoked [timemain
effect F(1,56)=10.586, p=0.002, ηp
2=0.159] from the pre-to-
post quit week [t(58)=11.91, p<0.001, r=0.84], and a re-
bound from post-quit to3 months post-quit [t(58)=5.49,
p<0.001, r=0.58] (descriptive statistics for these data are giv-
en in Table 2). Smoking levels 3 months post-quit smoking
were still lower overall than at baseline, however [t(58)=6.04,
p<0.001, r=0.62].
Survival analysis
Cox regression assessed relapse latency (descriptive statistics
of relapse data are shown Table 2) across the three groups. In
total, 8 cases were censored due to not having relapsed by
Table 1 Descriptive statistics (mean±standard deviation) and associated significance of tests of group means for smoking and mood variables at
baseline
MEM no REACT (N=20) PLAC+REACT (N=20) MEM+REACT (N=19) ANOVA significance
Age 27.45±6.91 28.35±7.04 29.32±9.9 0.769
Years in Education 15.33±1.98 16.45±3.02 15.47±2.9 0.304
Pre Quit FTND 5.4±1.05 5.6±1.05 5±0.75 0.15
Pre Quit Cigarettes Per Day 14.2±4.27 14.45±3.33 14.53±3.2 0.958
Years smoking 11.15±5.78 10.75±6.59 11.24±7.36 0.97
Pre Quit CO (ppm) 7.84±5.7 9.8±4.4 11.95±6.5 0.081
Number previous quits 2.11±1.2 2.45±1.7 2.53±2.25 0.736
Previous longest quit (days) 188.58±358.3 121.85±249.67 169.16±493.95 0.877
Last cigarette (mins) 833.7±184.51 248.45±294.94 204.16±227.08 0.416w
QSU Baseline 37.75±14.93 25.45±10.23 32±12.88 0.014*
MPSS Mood 0.96±0.69 0.63±0.35 0.72±0.48 0.185w
MPSS Urge Frequency 2.15±1.31 1.75±1.07 1.95±1.13 0.563
MPSS Urge strength 2.40±1.31 1.90±1.21 1.63±0.68 0.098
BIS Total 69.65±11.40 61.6±12.51 69.63±11.28 0.053
STAI 36.95±11.83 32.6±7.87 33.05±6.91 0.266
BDI 2.1±2.51 2.1±1.83 2.26±1.48 0.958
TEPS Anticipatory 4.56±0.79 4.7±0.58 4.59±0.77 0.815
TEPS Consummatory 4.59±0.84 4.74±0.8 4.72±0.79 0.818
PSS-FR 14.85±4.92 15.3±3.05 14.84±3.88 0.919
PSS-FA 11.75±6.23 12.6±5.92 10.53±6.34 0.576
All tests were one-way ANOVA except where marked with a subscript W, indicating that Welch’s ANOVAwas used due to heterogeneity of variance.
Ppm parts per million;*significant at p<0.05
Table 2 Descriptive statistics of
smoking outcomes across the
experimental groups
Group MEM no REACT PLAC+REACT MEM+REACT
Day 8 N Not smoking/still smoking 7/13 11/9 6/13
Day 8 N smoking less/smoking as much 15/5 18/2 12/7
Pre Quit week cigarettes per day 14.2±4.27 14.45±3.33 14.53±3.2
Post-quit week cigarettes per day 4.13±4.48 3.2±3.93 6.66±6.3
3 month cigarettes per day 7.91±6.45 8.55±7 10.44±5.45
Mean relapse latency (days) 22.7±78.97 95±151.44 47.32±110.85
Median relapse latency (days) 1±3.33 5±10 1±1.88
N guessing drug 1 9 9
N guessing placebo 7 4 6
N guessing don’t know 12 7 4
Mean andmedian relapse latency are given to illustrate that, although a few participants successfully quit for long
periods (affecting the mean latency statistic), most relapsed soon after quitting
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their final follow-up [MEM no REACT n=1; PLAC +
REACT n=5, MEM+REACT n=2]. Adding group to the ba-
sic regression model did not significantly improve model fit [-
2LL change=4.435, χ2 (2)=0.109]. Contrasts between regres-
sion slopes for each group found no significant differences
between any group (all ps>0.1) and entering craving and
baseline dependence as covariates did not significantly affect
the model (ps>0.1). A survival plot for these data is shown in
Fig. 2. Curves are plotted to 85 days as there was zero variance
in relapse status up to 365 days in all participants who were
abstinent at this time point.
Craving
Reductions in QSU craving were seen between days 1 and 8
[time main effect F(1,56)=19.333, p<0.001, ηp
2=0.257]. A
main effect of group was also observed [F(2,56)=5.788,
p<0.001, ηp
2=0.171], driven by higher craving on both days
in MEM no REACT than PLAC+REACT [t(38)=3.39, p=
0.004, r=0.48]. Day 1 QSU score was positively correlated
with day 8 smoking levels [r(59)=0.367, p=0.004] and atten-
tional bias to smoking images [r(59)=0.309, p=0.017] and
predicted 3-month FTND score [r(59)=0.5, p<0.001] and
shorter relapse latencies [r(59)=−0.367, p=0.004]. Overall,
there were no group differences in FTND [F(2, 56)=0.569,
p=0.569, η2=0.02] or cigarettes smoked per day [F(2, 56)=
0.355, p=0.703, η2=0.01] at 3 months post-quit or subse-
quently. There was thus no evidence for ‘lagged’ intervention
effec ts , as have previously been observed with
reconsolidation-based interventions (Soeter and Kindt 2015).
The MPSS showed decreases in urge to smoke frequency
[time main effect F(1,56)=6.393, p=0.014, ηp
2=0.102] and
strength [time main effect F(1,56)=4.778, p=0.033,ηp
2=
0.079] in all groups from day 1 to day 8, but no change in
mood [time main effect F(1, 56)=2.239, p=0.14, ns]. No
group or group×time effects were observed.
Smoking cue reactivity
Descriptive statistics for cue reactivity measures are presented
in Table 3. A 2 (day 1, day 8)×2 (pre-video, post-video)×3
(group) mixed ANOVA showed decreased craving in all
groups from days 1 to 8 [time main effect F(1,56)=22.114,
p<0.001, ηp
2=0.283] and a trend for an increase in craving
pre- to post-video on both days [pre-post main effect F(1,56)=
3.017, p=0.088, ηp
2=0.051]. No effects of group or interac-
tions were found. No effects of the video, group or study day
were observed for systolic blood pressure (all Fs < 2.3, ps>
0.1). For diastolic blood pressure, a main effect of group was
observed, with lower diastolic blood pressure in MEM no
REACT than PLAC + REACT and MEM + REACT overall
[group main effect F(2,56)=3.728, p=0.03, ηp
2=0.117], but
with no day, pre-post effects or interactions (all Fs < 1, ps>
0.45).
A 3 (time: pre-video, peri-video, post-video)×2 (day: day
1, day 8)×3 (group) ANOVA on HRV data (calculated at
standard deviation of R-R intervals; SDRR) found a quadratic
main effect of time [F(2, 112)=11.925, p<0.001, ηp
2=0.176],
with a reductionin HRV pre-to-peri video [t(58)=4.262,
p<0.001, r=0.49] and an increaseperi-to-post video [t(58)=
3.938, p=0.001, r=0.46]. A trend-level time×day×group in-
teraction was also found [F(4,112)=2.354, p=0067, ηp
2=
0.078] indicating that the reduction of HRV from pre-to-peri
video was significant only in the MEM no REACT group
[t(58)=2.917, p=0.015, r=0.36].
Fig. 2 Survival curves for
relapse latency by experimental
group, adjusted for craving.
Curves are censored at 85 days as
there was no change in relapse
status after this time point
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Skin conductance data (calculated asmean level of conduc-
tance in microSiemens) also showed a time main effect [F(2,
112)=47.211, p<0.001, ηp
2=0.457], with conductance in-
creasing in a linear fashion from pre-to-peri [t(58)=4.01, p=
0.001, r=0.47] and peri-to-post video [t(58)=7.197, p<0.001,
r=0.69]. This was qualified by a day×time interaction [F(2,
112)=3.688, p=0.029, ηp
2=0.062], with skin conductance
rising across all time points but not pre-video to peri-video
on day 8 [t(58)=0.91, p=0.429, r=0.12]. Together, these find-
ings provide no evidence for effects of the intervention on cue
reactivity.
Visual probe
Dwell times were assessed independently for 500-ms trials
and 2000-ms trials, as initial and maintained attentional bias
can be pharmacologically dissociated in smokers (Freeman
et al. 2014). Two (type: smoking-image-containing pairs, neu-
tral pairs)×2 (target: target image, control image)×3 (group)
mixed ANOVAs were used to assess all eye-tracking data.
Five hundred-millisecond trials showed effects of type
[F(1,56)=5.729, p=0.02, ηp
2=0.093], target [F(1,56)=
5.295, p=0.025, ηp
2=0.086] and a type×target [F(1,56)=
7.428, p=0.009, ηp
2=0.117] and type×target×group interac-
tion [F(2,56)=3.31, p=0.043, ηp
2=0.106]. The target×type
interaction confirmed the salienceof the smoking cues utilised,
evidenced by greater dwell times on smoking target images in
the smoking-control pairs [t(58)=3.183, p=0.002, r=0.39]
but not in neutral-neutral pairs [t(58)=0.29, n.s]. The type×
target×group interaction indicated higher levels of attentional
bias in MEM no REACT than PLAC + REACT and MEM+
REACT, evidenced by greater dwell time on the smoking
target vs. control image in MEM no REACT [t(58)=3.846,
p<0.001, r=0.45], but not in MEM+REACT and PLAC+
REACT [ts< 1, n.s.]
The 2000-ms dwell times showed type [F(1,56)=22.706,
p<0.01, ηp
2=0.288] and borderline type×target interaction
effects [F(1,56)=3.891, p=0.053, ηp
2=0.065], indicating
greater overall dwell on to image pairs containing a smoking
image and, within these pairs, borderline longer looking at the
smoking target image [t(58)=2.01, p=0.05, r=0.25]. First,
fixation times showed effects of target F(1,56)=10.004, p=
0.003, ηp
2=0.152] and a target×type interaction F(1,56)=
6.617, p=0.013, ηp
2=0.106]. The interaction indicated more
rapid fixations on smoking target images than control images
[t(58)=5.376, p<0.001, r=0.58], with no difference in initial
fixation times in neutral-neutral pairs [t<0.5, n.s.]. This rapid
attentional capture by smoking-related images is indicative of
intact motivational salience of these cues.
Drug blindness check
A chi square of group×participant’s guess on drug (‘don’t
know’, ‘drug’, ‘placebo’) found a significant effect of group
[χ2(4)=11.74, p=0.019]. Standardised residuals showed that
this was driven by fewer participants in the MEM no REACT
believing they received the active drug than the other two
groups. Guess frequencies are shown in Table 2.
Manipulation check on reactivation task
All participants in the MMM reactivation conditions correctly
recorded the contents of at least three of the six smoking clips.
Although the free recall did not explicitly prompt participants
Table 3 Descriptive statistics for measures of smoking cue reactivity
MEM No REACT PLAC+REACT MEM+REACT
Pre Peri Post Pre Peri Post Pre Peri Post
SCL Day 1 (μS) 3.16±2.91 3.58±3.62 4.5±4.05 3.84± 2.16 4.70±2.22 5.54±2.68 4.47±2.83 5.13±3.18 6.05± 3.61
SCL Day 8 (μS) 3.57±2.6 4.04±3.12 4.85±3.64 3.57±1.86 3.6±2.06 4.23±2.53 4.27±2.64 4.39±2.53 5.42± 2.87
HRV day 1 (SDRR) 10.14±6.57 6.86±4.8 8.34±4.34 6.87±3.81 5.58±4.05 7.46±4.34 7.05±3.75 6.08±4.13 7.69± 4.35
HRV day 8 (SDRR) 9.53± 5.42 7.86±5.39 10.64±5.66 7.92±4.18 7.25±7.37 7.79±5.57 8.17± 4.70 5.69±3.70 6.71± 3.97
Craving day 1 48.3±14.87 – 46.55±22.75 41.73±27.93 – 49±27.18 48.5±25.77 – 53.7±31.78
Craving day 8 34.7±25.95 – 35.19±24.64 22.55±17.47 – 25.8±22.75 29.42±26.75 – 39.37±34.12
Systole day 1
(mmHg)
106.9±11.9 – 105.1±9.35 110.25±15.21 – 108±14.70 108.84±13.12 – 109.9±14.87
Diastole day 1
(mmHg)
65.25±6.91 – 66.4±5.932 71.3±12.13 – 71.7±10.87 70.74±9.83 – 71.95±10
Systole day 8
(mmHg)
103.2±10.13 – 101.55±8.44 109.35±12.59 – 107.5±13.52 109.47±15.77 – 110.4±15.42
Diastole Day 8
(mmHg)
63.9±8.12 – 65.3±4.47 71.85±10.25 – 70.45±9.47 71.11±11.13 – 71.37±9.91
Data represent means±SD
SCL skin conductance level, HRV heart rate variability, μS micro Siemens, SDRR standard deviation of R-R intervals, mmHg millimetres of Mercury
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to record whether they believed ‘completing the task’ meant
smoking a cigarette in the MMM reactivation conditions, all
participants in these groups reported that made some reference
to their own smoking and 28 of the 39 participants in this
group mentioned smoking a cigarette from the box. For the
non-reactivation condition, participants again correctly
summarised at least three of the scenes. Four participants re-
ported that theyhad been thinking about smoking while
watching the control scenes. Re-analysing the data with these
participants reclassified as MEM + REACT made no substan-
tive difference to the results. No participants in this group
reported that they believed the task would involve smoking.
Discussion
Employing a translational medicine paradigm with healthy
volunteers, we assessed the possibility of inhibiting the
reconsolidation of maladaptive cue-smoking memories with
memantine in voluntarily quitting cigarette smokers. Ten mil-
ligrams of memantine in combination with smoking cue mem-
ory retrieval did not significantly impact smoking levels, la-
tency to relapse, craving, cue salience or reactivity to
smoking-related stimuli, indicating that memantine did not
block the reconsolidation of retrieved cue-smoking MMMs.
Indeed, there was some mild evidence of worsening outcomes
following memantine, with lower (but non-significant) relapse
latency in groups receiving drug. In the group receiving
memantine with no memory reactivation, greater attentional
bias to smoking cues at test was seen than the groups under-
going memory reactivation with either placebo or memantine.
However, the former group experienced higher craving prior
to and after capsule treatment and lower belief in receiving the
active drug. The observed correlations between pre-
reactivation craving, shorter relapse latency, day 8 smoking
and attentional bias suggest that greater tonic craving and
reduced expectancy effects in this group may be responsible
for this finding. Regardless, memantine with MMM retrieval
did not improve relapse latency or smoking outcomes, the
clinical outcomes of greatest importance in this study. Thus,
no evidence for blockade of MMM reconsolidation by
memantine was found in the current study. We believe that
these results contribute important insights into priority areas
for the successful translation of reconsolidation-based thera-
pies to human addicts.
The high rates of short-latency relapse observed here are
typical of smoking cessation and may have masked interven-
tion effects by reducing power to assess long-term group dif-
ferences. The physiological allostatic drivers of early
relapseare likely unaffected by MMM reconsolidation block-
ade, whereas later, following homeostatic restoration,
sensitised mnemonic reward systems play a more significant
role in relapse. Reconsolidation-blocking treatments may best
employed as relapse-preventing, rather than abstinence-
promoting interventions (Milton and Everitt 2012), or may
need to be employed in combination with withdrawal man-
agement strategies such as nicotine replacement therapy.
Given this, it is possible that, had a follow-up session more
proximal to intervention been employed (e.g. day 1 + 24 or
48 h), effects of intervention may have been seen. However,
the great promise of reconsolidation-basedMMM interference
lies in its potential therapeutic longevity. Indeed, long-term
follow-up periods in smoking studies are the true test of effi-
cacious interventions.
Reconsolidation interference represents the most via-
ble current target for persistently reducing the potency
of consolidated MMMs. Previously, attempts to translate
preclinical memory-based SUD pharmacotherapies have
persevered despite a lack of a cohesive methodological
framework or taking account of the methodological
shortcomings of previous research (Das and Kamboj
2012; Kamboj et al. 2012; Kamboj et al. 2011), incur-
ring substantial financial and research costs. The meth-
odological and epistemic issues in the current research
highlight necessary areas of experimental refinement in
response to the observed null results, which, whilst be-
ing mindful of clinical relevance, should take precedent
in the advancement of this field.
As reconsolidation of drug memories is a ‘silent’ process,
only inferred via interference during the reconsolidation win-
dow, an epistemological problem exists for null findings
which may be attributable to a drug’s inefficacy in interfering
with restabilisation, or a lack ofmemory destabilisation during
retrieval. In order to disentangle these, retrieval procedures
that consistently destabilise MMMs and alternative com-
pounds that effectively and consistently block restabilisation
are required.
In animals, robust blockade of restabilisation of MMMs is
achieved using compounds that interfere directly or upstream
of neuronal protein synthesis or transcription. This action
makes these compounds highly toxic and unsuitable for hu-
man use. To date, no drug has shown reliable and lasting
reduction in drug use via blockade of MMM reconsolidation
in humans. For safety and tolerability, memantine is an attrac-
tive NMDAR antagonist for use in the context of interfering
with human MMM reconsolidation. However, the current
findings do not support this application. Although the current
dose was low, memantine (Creeley et al. 2006) shares with
other NMDAR antagonists (Das et al. 2013) a complex, non-
linear dose-response relationship in mnemonic function im-
plying that optimal dosing for is not simply a case of ‘more-
is-better’. Despite this, given the lack of evidence of a
memantine effect on almost any measure, it may be that
10 mg was simply too low a dose to observe effects on
reconsolidation and it would be prudent to assess higher doses
of the drug for reconsolidation blockade. Memantine also has
Psychopharmacology (2015) 232:3363–3374 3371
unique kinetic properties at the NMDAR (Black et al. 1996;
Blanpied et al. 1997) which may be undesirable in the context
of blocking memory restabilisation. In particular, it may not
produce the sustained level of NMDAR blockade necessary
for disruption in synaptic plasticity during the temporally lim-
ited reconsolidation window due to its relatively low affinity,
rapid off-rate receptor kinetics (Rammes et al. 2008) and pref-
erence for extrasynaptic rather than synaptic NMDARs (Xia
et al. 2010).
In contrast, MK-801 (Dizoclipine), the prototypical antag-
onist for reconsolidation blockade – is paradigmatic with re-
gard to its selectivity, affinity, voltage-dependence and essen-
tial irreversibility of blockade during memory destabilisation.
The dissociative and psychotomimetic effects are products of
the same kinetic profile at NMDARs that cause robust inter-
ference with restabilisation, so these effects may be necessary
when blocking MMM reconsolidation via NMDARs. While
neurotoxicity precludes the use of MK 801 in humans, keta-
mine may be a realistic alternative. It is approved for human
use despite its side effects and already shows some promise
for the treatment of SUDs (Krupitsky and Grinenko 1997).
Oral memantine’s slow peak plasma latencymeans it must
be administered prior to memory retrieval in order to peak
post-retrieval. As activation of GluN2b subunit-containing
NMDARs is required for memory destabilisation at recall,
prior antagonism can reduce the ability of memories to
destabilise (Mamou et al. 2006), keeping them in a
plasticity-resistant state. Given that both groups receiving
memantine had slightly (but not significantly) poorer relapse
latencies than those receiving placebo, it is possible that this
occurred in the current study. Further, NMDAR blockade can
engender aberrant prediction error, potentially interfering with
successful destabilisation or producing paradoxical effects on
memory retention (Corlett et al. 2013). In the current study
(and indeed future studies using oral preparations of
NMDAergic drugs), this complicates interpretation of find-
ings and may be responsible for observed null findings.
However, animal studies have previously administered
NMDA antagonists systemically prior to reactivation and
shown successful reconsolidation blockade (Milton et al.
2008a; Wu et al. 2012), so pre-reactivation dosing effects
likely depend upon locus of administration (Mamou et al.
2006) and selectivity for GluN2b vs GluN2a receptor sub-
types (Milton et al. 2013). Dosing after retrieval is ideal as it
removes this potential confound. However, for drugs like
memantine with long latency to peak activity, this would po-
tentially allow some restabilisation of memory traces before
sufficient NMDAR blockade was achieved, reducing the effi-
cacy of the intervention (Milton et al. 2008a; Wu et al. 2012).
Ideally, then, NMDARs should be rapidly antagonised, with
high receptor saturation, following memory destabilisation.
This may preclude the use of oral preparations of
NMDAergic drugs for this purpose and will likely require
intravenous dosing post-reactivation. If these formulations
prove ineffective in reducing MMM strength, NMDAR an-
tagonism may need to be abandoned as a pharmacological
target in favour of alternative receptor pathways implicated
in memory restabilisation (Blundell et al. 2008; Carrera et al.
2012; de Oliveira Alvares et al. 2008; Makkar et al. 2010).
Identifying tolerated pharmacological means for consistently
blocking MMM reconsolidation in humans will be key in
moving this field forward.
We designed the reactivation procedure used here in an
attempt to maximise the potential for memory destabilisation
by presenting prototypical smoking cues and engendering un-
certainty about reinforcement. This is equivalent to the proto-
typical reminder without reinforcement in animal
reconsolidation studies. We told participants they ‘may or
may not be required to complete the task’ (i.e. smoke) follow-
ing the cue videos, while withholding reward. This aimed to
generate prediction error following retrieval, thought to be key
in destabilising memories (Sevenster et al. 2013). If however,
the reactivation task did not create the expectation of smoking,
the possibility of negative prediction occurring would be pre-
cluded. Participants’ free-response summary of the reactiva-
tion procedure suggests that those in the MMM reactivation
groups were thinking about smoking the cigarettes presented
in the box. We were, however, unable to collect an indepen-
dent measure of reward prediction error in the current study;
therefore, a potential explanation for the null findings remains.
Given the age and strength (Gräff et al. 2014; Robinson and
Franklin 2010) of the smoking MMMs targeted here, it is
possible that the reminder structure did not sufficiently
destabilise these traces. Although preclinical literature does
not always explicitly aim to generate prediction error in re-
minder procedures, it is likely that PE occurs at retrieval
to some extent in preclinical studies, as reminder cues
are typically not reinforced during reactivation proce-
dures and learning has generally not reached ceiling
level. With the asymptotic levels of learning that are
present with MMMs in smoking, prediction error mag-
nitude is retrieval are likely to be low (Schultz et al.
1997) in the absence of procedures that explicitly aim
to maximise this parameter.
Alternatively, it is possible that reconsolidation simply
does not occur at any meaningful level for memories as
strongly encoded as cue-smoking memories in daily smokers.
Many researchers have identified the potential of
reconsolidation interference for treating SUDs; however, there
is a notable paucity of human research directly assessing this.
The current research shows that we need to re-assess whether
destabilisation of extremely robustly trained MMMs is possi-
ble and, if so, what retrieval procedures can reliably produce
these effects.
In summary, we found no evidence for 10 mg
memantine blocking the reconsolidation of cue-smoking
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memories in any measure of cue reactivity, craving, sa-
lience or relapse in quitting smokers. While memantine in
combination with memory reactivation does not appear to
be a clinically useful strategy for smoking cessation, the
current findings highlight important methodological and
epistemological issues in human reconsolidation that must
be addressed research to allow the accurate assessment of
the clinical potential of post-destabilisation interventions
for SUDs.
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